The Cherian Lab: Developing Translational Treatments

The Cherian Lab at the OSUCCC – James, led by cancer research expert, breast medical oncologist and Principal Investigator Mathew Cherian, MBBS, is dedicated to improving the quality of life for patients with breast cancer by using clinical data to formulate treatment strategies and develop novel therapies.

The Cherian Lab studies breast cancer by looking at endocrine resistance, estrogen receptor signaling and chemotherapy resistance.


At the OSUCCC – James, The Cherian Lab’s mission is to work toward a breast cancer cure while improving patient quality of life.

The team of experts selects projects that have the highest potential to translate to the clinic, studying actual mechanisms and pathways aimed at impacting patient care directly. The Cherian Lab researchers and scientists are inspired by the fact that the treatments they research may make a real difference in patients lives.

Who We Are

The OSUCCC – James Cherian Lab is led by Principal Investigator Mathew Cherian, MBBS, a medical oncologist who specializes in treating patients who have been diagnosed with breast cancer.

Cherian is both a nationally recognized clinician and scientist who is motivated by his direct patient care experience as well as how each patient’s cancer behaves clinically. The lab’s goal: to improve the care of all patients through his team’s collaborative work with basic science.

With extensive experience in breast cancer diagnosis, treatment, care and research, Cherian’s goal is to translate the team’s bench research into clinically effective therapies.

How We Do It

The Cherian Lab’s goal originates from Mathew Cherian’s experience in both the lab and the clinic.

The therapies studied in The Cherian Lab are highly influenced by his extensive experience with direct patient care. These specialists utilize clinical data to research and formulate treatment options and strategies that have a high likelihood of turning into successful bedside therapies.

The Cherian Lab is specifically studying estrogen receptor signaling pathways to determine and demonstrate its relevance in hormone positive breast cancers, testing compounds that may be used in clinical trials if pre-clinical models provide efficacy.

Collaboration is an integral part of the Cherian Lab’s work, teaming with nationally and internationally recognized colleagues in medical oncology, radiation oncology, surgical oncology and pathology.

Additionally, the lab is supported by the Ohio State University Comprehensive Cancer Center, the Drug Development Institute, the Division of Medical Oncology, and the Center for Clinical Translation Sciences.

These collaborations put the Cherian Lab team in a unique position to test compounds that are accessible only at Ohio State.

Breakthroughs and Discoveries

The OSUCCC – James Cherian Lab is interested in studying and targeting singular pathways to improve patient outcomes. The team is currently testing cell lines, xenografts and more, researching estrogen beta receptor efficacy as a therapeutic strategy in estrogen receptor positive breast cancer with a compound that may be translatable to patient treatments if found effective in pre-clinical models.

If found effective, the research will move to clinical trial.

Collaboration With Other OSU Labs and Research Teams

When recruiting for the Cherian Lab, Principal Investigator Mathew Cherian, MBBS, looks for people who understand the basic mechanisms behind the experiments performed in the lab, who can elucidate novel ideas and who can analyze and explain the data gathered. The team looks for researchers who share the same motivation to improve patients lives through the studies performed in the lab.

The Cherian Lab values collaboration and is currently supported by the Ohio State University Comprehensive Cancer Center, the Drug Development Institute, the Division of Medical Oncology and the Center for Clinical Translation Sciences.

The team looks for collaborators with similar interests and who are focused on curing cancer -- researchers who can bring study techniques to the lab that are complementary to what they do.

For more information on the team, collaborations and opportunities, please contact Mathew Cherian’s office at 800-293-5066; send correspondence to: Dr. Mathew Cherian, c/o The Stefanie Spielman Comprehensive Breast Center, 1145 Olentangy River Rd., Columbus, OH 43212; or email

Mathew Cherian, MBBS

Mathew Cherian


Dr. Cherian specializes in the clinical care of patients with breast cancer and in using molecular techniques to dissect the pathogenesis of cancer.

Learn More

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator